P0024The Usefulness of Tissue Calprotectin in Pediatric Crohn’s Disease—A Pilot Study

Background Fecal calprotectin (FCP) is a highly sensitive biomarker of intestinal inflammation widely used in diagnostics and monitoring of inflammatory bowel disease (IBD). Immunohistochemical assessment of calprotectin in the bowel mucosa is not a diagnostic standard. Therefore, the aim of this study was to evaluate tissue calprotectin (TCP) as a potential marker providing added insight for pediatric patients with Crohn’s disease (CD). Methods Fecal and tissue calprotectin were measured in children with CD. The values were correlated with disease activity and histopathological changes of the patients’ endoscopic biopsies. Disease activity was assessed using the Pediatric Crohn’s Disease Activity Index (PCDAI); fecal calprotectin (FCP) was measured with the ELISA test. Immunohistochemical (IHC) staining for calprotectin antigen was performed on the biopsy samples from six bowel segments, and the number of TCP cells was counted per high power field (HPF). Non-parametric statistical tests were used for data analysis Results Fifty-seven children with CD with a median age of 10.5 (1–17) years (yrs) were examined for fecal and tissue calprotectin. The patients’ median PCDAI score was 10 (0–63.5), while median FCP was 535 (30–600) µg/g. We observed a correlation between disease activity (PCDAI) and FCP, TCP in inflammatory lesions and in crypts. There was no association either between FCP and TCP or between TCP in epithelium and PCDAI. Conclusion It seems that IHC detection of calprotectin in bowel mucosa to assessdisease behavior may be useful. FCP is a gold-standard biomarker in the diagnosis, monitoring andprognosis of IBD, and its levels correlated well with clinical activity in our study group. References: 1.Michielan, A.; D’Incà, R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapyof Leaky Gut. Mediat. Inflamm. 2015, 2015, 628157. [CrossRef] [PubMed] 2.Gomollón, F.; Dignass, A.; Annese, V.; Tilg, H.; Van Assche, G.; Lindsay, J.O.; Peyrin-Biroulet, L.; Cullen, G.J.; Daperno, M.;Kucharzik, T.; et al. ECCO 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016:Part 1: Diagnosis and Medical Management. J. Crohn’s Colitis 2017, 11, 3–25. [CrossRef] [PubMed] 3.Magro, F.; Gionchetti, P.; Eliakim, R.; Ardizzone, S.; Armuzzi, A.; Barreiro-de Acosta, M.; Burisch, J.; Gecse, K.B.; Hart, A.L.;Hindryckx, P.; et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1:Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J.Crohn’s Colitis 2017, 11, 649–670. [CrossRef] [PubMed] 4.Piton, G.; Capellier, G. Biomarkers of gut barrier failure in the ICU. Curr. Opin. Crit. Care 2016, 22, 152–160. [CrossRef] [PubMed] 5.Pang, T.; Leach, S.T.; Katz, T.; Day, A.S.; Ooi, C.Y. Fecal Biomarkers of Intestinal Health and Disease in Children. Front. Pediatr.2014, 2, 6. [CrossRef] [PubMed] 6.Canani, R.B.; Rapacciuolo, L.; Romano, M.T.; de Horatio, L.T.; Terrin, G.; Manguso, F.; Cirillo, P.; Paparo, F.; Troncone, R.Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig. Liver Dis. 2004, 36, 467–470. [CrossRef][PubMed] 7.Montalto, M.; Gallo, A.; Santoro, L.; D’Onofrio, F.; Landolfi, R.; Gasbarrini, A. Role of fecal calprotectin in gastrointestinaldisorders. Eur. Rev. Med. Pharmacol. Sci. 2013, 17, 1569–1582. [CrossRef] [PubMed] 8.Carroccio, A.; Iacono, G.; Cottone, M.; Di Prima, L.; Cartabellotta, F.; Cavataio, F.; Scalici, C.; Montalto, G.; Di Fede, G.; Rini, G.;et al. Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable BowelSyndrome: A Prospective Study in Adults and Children. Clin. Chem. 2003, 49, 861–867. [CrossRef] 9.Gaya, D.R.; Mackenzie, J.F. Faecal calprotectin: A bright future for assessing disease activity in Crohn’s disease. QJM 2002, 95,557–558. [CrossRef] [PubMed] 10. Gastrointest. Disord. 2023, 5 3610. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. Misteli, H.; Koh, C.E.; Wang, L.M.; Mortensen, N.J.; George, B.; Guy, R. Myenteric plexitis at the proximal resection margin is apredictive marker for surgical recurrence of ileocaecal Crohn’s disease. Color. Dis. 2015, 17, 304–310. [CrossRef] [PubMed] 11. Ferrante, M.; de Hertogh, G.; Hlavaty, T.; D’Haens, G.; Penninckx, F.; D’Hoore, A.; Vermeire, S.; Rutgeerts, P.; Geboes, K.; vanAssche, G. The Value of Myenteric Plexitis to Predict Early Postoperative Crohn’s Disease Recurrence. Gastroenterology 2016, 130,1595–1606. [CrossRef] [PubMed] 12. Simillis, C.; Jacovides, M.; Reese, G.E.; Yamamoto, T.; Tekkis, P.P. Meta-analysis of the role of granu-lomas in the recurrence ofCrohn disease. Dis. Colon. Rectum. 2010, 53, 177–185. [CrossRef] [PubMed] 13. Li, Y.; Ge, Y.; Zhu, W.; Gong, J.; Cao, L.; Guo, Z.; Gu, L.; Li, J. Increased enteric glial cells in proxi-mal margin of resection isassociated with postop- erative recurrence of Crohn’s disease. J. Gastroenterol. Hepatol. 2018, 33, 638–644. [CrossRef] [PubMed] 14. Fukunaga, S.; Kuwaki, K.; Mitsuyama, K.; Takedatsu, H.; Yoshioka, S.; Yamasaki, H.; Yamauchi, R.; Mori, A.; Kakuma, T.; Tsuruta,O.; et al. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.Int. J. Mol. Med. 2018, 41, 107–118. [CrossRef] [PubMed] 15. Guirgis, M.; Wendt, E.; Wang, L.M.; Walsh, A.; Burger, D.; Bryant, R.V.; Kent, A.; Adamson, R.; Brain, O.; Travis, S.P.L.; et al.Beyond Histological Remission: Intramucosal Calprotectin as a Potential Pre-dictor of Outcomes in Ulcerative Colitis. J. CrohnsColitis 2017, 11, 460–470. [CrossRef] [PubMed] 16. Liu, W.-B.; Lü, Y.-M.; Jin, Z.; Yang, X.-L. Expression of calprotectin in colon mucosa and fecal of patients with ulcerative colitis. J.Peking Univ. Health Sci. 2005, 37, 179–182.Fabian, O.; Hradsky, O.; Lerchova, T.; Mikus, F.; Zamecnik, J.; Bronsky, J. Limited clinical significance of tissue calprotectin levelsin bowel mucosa for the prediction of complicated course of the disease in children with ulcerative colitis. Pathol. Res. Pract. 2019,215, 152689. [CrossRef] [PubMed] 17. Zarubova, K.; Fabian, O.; Hradsky, O.; Lerchova, T.; Mikus, F.; Dotlacil, V.; Pos, L.; Skaba, R.; Bron-sky, J. Predictive value of tissuecalprotectin for disease recurrence after ileocecal resection in pediatric Crohn’s disease. BioMed Pap. Med. Fac. Univ. Palacky.Olomouc. Czech Repub. 2022, 166, 297–303. [CrossRef] [PubMed] 18. Khaki-Khatibi, F.; Qujeq, D.; Kashifard, M.; Moein, S.; Maniati, M.; Vaghari-Tabari, M. Calprotectin in inflamma-tory boweldisease. Clin. Chim. Acta 2020, 510, 556–565. [CrossRef] [PubMed] 19. Rokkas, T.; Portincasa, P.; Koutroubakis, I.E. Fecal calprotectin in assessing inflammatory bowel disease endo-scopic activity: Adiagnostic accuracy meta-analysis. J. Gastrointestin. Liver Dis. 2018, 27, 299–306. Conflict of interest: Dr. Szymanska, Sylwia: No conflict of interest Karkucisnka-Wieckowska, Agnieszka: No conflict of interest Dadalski, Maciej: No conflict of interest Kierkuś, Jarosław: Grant: Nestle Other: Egis, Nutricia, Abbvie, Mundipharma, Nestle Szymanska, Edyta: No conflict of interests